NOT-TR-20-020: Notice of NCATS Withdrawal from Participation in PAR-18-691, "Innovative Therapies and Tools for Screenable Disorders in Newborns (R21 Clinical Trial Optional)

Notice of NCATS Withdrawal from Participation in PAR-18-691, "Innovative Therapies and Tools for Screenable Disorders in Newborns (R21 Clinical Trial Optional)

Notice Number: NOT-TR-20-020

Key Dates
Release Date: April 8, 2020

Related Announcements
PAR-18-691 Innovative Therapies and Tools for Screenable Disorders in Newborns (R21 Clinical Trial Optional)

Issued by
National Center for Advancing Translational Sciences (NCATS)

Purpose

The purpose of this Notice is to inform prospective applicants that, effective immediately, the National Center for Advancing Translational Sciences (NCATS) is no longer participating in PAR-18-691 “Innovative Therapies and Tools for Screenable Disorders in Newborns (R21 Clinical Trial Optional)”. NCATS will no longer accept applications submitted to this Funding Opportunity Announcement.

Inquiries

Please direct all inquiries to:

NCATS Referral Office
Email: [email protected]